TG100-115 is a small molecule drug that acts as a multi-kinase inhibitor. It was developed by TargeGen Inc., a biopharmaceutical company that was later acquired by Sanofi. The chemical name of TG100-115 is (3S)-3-[[4-(Aminocarbonyl)-2,6-dimethylphenyl]amino]-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-acetamide. Its molecular formula is C19H20N6O2, and its formula weight is 364.40 g/mol. The compound has a CAS number of 677297-51-7.
Top ten keywords from Google for TG100-115 include:
Some synonyms for TG100-115 include:
Health benefits of TG100-115 have been studied in preclinical models and clinical trials. The drug has shown potential as a cancer treatment by inhibiting multiple kinases associated with tumor growth and progression. It has also demonstrated anti-inflammatory and neuroprotective effects that may be useful in treating diseases such as multiple sclerosis and Alzheimer's disease. Additionally, TG100-115 has been shown to improve insulin sensitivity and glucose metabolism, suggesting a potential role in diabetes treatment.
The mechanism of action of TG100-115 involves inhibition of multiple kinases, including PI3K, BTK, and JAK2. These kinases are involved in cell signaling pathways that regulate cell growth, survival, and immune function. By blocking these pathways, TG100-115 can prevent cancer cells from proliferating and reduce inflammation in various tissues.
In terms of safety, TG100-115 has been generally well-tolerated in clinical trials. However, like all drugs, it can cause side effects. Common side effects include nausea, fatigue, and diarrhea. More serious adverse events, such as liver toxicity and hematologic abnormalities, have been reported at higher doses or with long-term use.
Dosing information for TG100-115 varies depending on the indication and stage of disease. In clinical trials, doses have ranged from 50 mg to 800 mg per day. The drug is typically administered orally as a tablet or capsule.
In conclusion, TG100-115 is a small molecule drug that acts as a multi-kinase inhibitor. It has shown promising results in preclinical models and clinical trials for cancer, inflammation, and neurodegenerative diseases. Although it appears to be generally safe, it can cause side effects and more research is needed to fully understand its long-term effects. Overall, TG100-115 represents a potentially important therapeutic option for a range of diseases and warrants further investigation.
